COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that Robert Alexander, Ph.D, ZS Pharma’s chairman and chief executive officer, will present at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in the Elizabethan D room, in San Francisco, CA, on Wednesday, January 15, 2014, at 9:30 a.m. PST.
About ZS Pharma
ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas. ZS Pharma’s lead therapeutic candidate, ZS-9, is in Phase 3 clinical trials. It is being developed to treat hyperkalemia, a potentially life-threatening metabolic condition characterized by an abnormally high serum concentration of potassium. ZS Pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases. Additional information is available at www.zspharma.com.